The Office Evaluation of Weakness

ABSTRACT

The office evaluation of weakness can be a daunting task. Many different disorders affecting many different parts of the nervous system can manifest with “weakness,” and several nonneurologic conditions may present with complaints of weakness. It is the job of the neurologist to determine whether a patient has neurologic weakness or suffers simply from fatigue. The physician then must properly localize the pathophysiologic site of weakness. The author focuses on neuromuscular causes of weakness affecting muscle, the neuromuscular junction, peripheral nerve, or the anterior horn cell. General historical and examination clues to localization will be discussed. A localization-based evaluation will be outlined, with more specific recommendations regarding the evaluation of a few specific disorders offered. Localization-specific laboratory, electrodiagnostic, imaging, and pathologic investigations will be presented.

KEYWORDS

Weakness - myopathy - myasthenia gravis - multifocal motor neuropathy - amyotrophic lateral sclerosis

REFERENCES

• 1 Merriam-Webster. Fatique. Available at: http://www.merriam-webster.com/medlineplus/fatigue Accessed June 1, 2010
• 2 Baker S B, Worthley L I. The essentials of calcium, magnesium and phosphate metabolism: part II. Disorders.  Crit Care Resusc. 2002;  4 (4) 307-315
• 3 Riggs J E. Neurologic manifestations of electrolyte disturbances.  Neurol Clin. 2002;  20 (1) 227-239, vii
• 4 Alshekhlee A, Kaminski H J, Ruff R L. Neuromuscular manifestations of endocrine disorders.  Neurol Clin. 2002;  20 (1) 35-58, v–vi
• 5 Bordelon P, Ghetu M V, Langan R C. Recognition and management of vitamin D deficiency.  Am Fam Physician. 2009;  80 (8) 841-846
• 6 Ziambaras K, Dagogo-Jack S. Reversible muscle weakness in patients with vitamin D deficiency.  West J Med. 1997;  167 (6) 435-439
• 7 Hinshaw D B, Carnahan J M, Johnson D L. Depression, anxiety, and asthenia in advanced illness.  J Am Coll Surg. 2002;  195 (2) 271-277 discussion 277-278
• 8 Ruttenber A J, McAnally H B, Wetli C V. Cocaine-associated rhabdomyolysis and excited delirium: different stages of the same syndrome.  Am J Forensic Med Pathol. 1999;  20 (2) 120-127
• 9 Walsh R J, Amato A A. Toxic myopathies.  Neurol Clin. 2005;  23 (2) 397-428
• 10 Dresser L P, Massey E W, Johnson E E, Bossen E. Ipecac myopathy and cardiomyopathy.  J Neurol Neurosurg Psychiatry. 1993;  56 (5) 560-562
• 11 Mastaglia F L. Drug induced myopathies.  Pract Neurol. 2006;  6 4-13
• 12 Gaist D, Rodríguez L A, Huerta C, Hallas J, Sindrup S H. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study.  Epidemiology. 2001;  12 (5) 565-569
• 13 Bradley W G, Lassman L P, Pearce G W, Walton J N. The neuromyopathy of vincristine in man. Clinical, electrophysiological and pathological studies.  J Neurol Sci. 1970;  10 (2) 107-131
• 14 Srinivasan J, Wu C J, Amato A A. Inflammatory myopathy associated with imatinib mesylate therapy.  J Clin Neuromuscul Dis. 2004;  5 (3) 119-121
• 15 Pulipaka U, Lacomis D, Omalu B. Amiodarone-induced neuromyopathy: three cases and a review of the literature.  J Clin Neuromuscul Dis. 2002;  3 (3) 97-105
• 16 Wilbur K, Makowsky M. Colchicine myotoxicity: case reports and literature review.  Pharmacotherapy. 2004;  24 (12) 1784-1792
• 17 Casado E, Gratacós J, Tolosa C et al.. Antimalarial myopathy: an underdiagnosed complication? Prospective longitudinal study of 119 patients.  Ann Rheum Dis. 2006;  65 (3) 385-390
• 18 Kwon J-B, Kleiner A, Ishida K, Godown J, Ciafaloni E, Looney Jr R J. Hydroxychloroquine-induced myopathy.  J Clin Rheumatol. 2010;  16 (1) 28-31
• 19 Authier F J, Chariot P, Gherardi R K. Skeletal muscle involvement in human immunodeficiency virus (HIV)-infected patients in the era of highly active antiretroviral therapy (HAART).  Muscle Nerve. 2005;  32 (3) 247-260
• 20 Tunn U W, Wiedey K. Safety and clinical efficacy of a new 6-month depot formulation of leuprorelin acetate in patients with prostate cancer in Europe.  Prostate Cancer Prostatic Dis. 2009;  12 (1) 83-87
• 21 Sobaci G, Erdem U, Durukan A H et al.. Safety and effectiveness of interferon alpha-2a in treatment of patients with Behcet's uveitis refractory to conventional treatments. Ophthalmology. Available at: http://dx.doi.org/10.1016/j.ophtha.2009.11.022 Accessed June 1, 2010
• 22 Shaiova L. The management of opioid-related sedation.  Curr Pain Headache Rep. 2005;  9 (4) 239-242
• 23 Aapro M S, Cella D, Zagari M. Age, anemia, and fatigue.  Semin Oncol. 2002;  29 (3, Suppl 8) 55-59
• 24 Meeus M, Mistiaen W, Lambrecht L, Nijs J. Immunological similarities between cancer and chronic fatigue syndrome: the common link to fatigue?.  Anticancer Res. 2009;  29 (11) 4717-4726
• 25 Clauw D J. Fibromyalgia: an overview.  Am J Med. 2009;  122 (12, Suppl) S3-S13
• 26 Mioxham J, Jolley C. Breathlessness, fatigue and the respiratory muscles.  Clin Med. 2009;  9 (5) 448-452
• 27 Shizukuda Y, Plummer S L, Harrelson A. Customized exercise echocardiography: beyond detection of coronary artery disease.  Echocardiography. 2010;  27 (2) 186-194
• 28 Newton J L. Systemic symptoms in non-alcoholic fatty liver disease.  Dig Dis. 2010;  28 (1) 214-219
• 29 Stenholm S, Kronholm E, Sainio P et al.. Sleep-related factors and mobility in older men and women.  J Gerontol A Biol Sci Med Sci. 2010;  65 (6) 649-657
• 30 Dhruva A, Dodd M, Paul S M et al.. Trajectories of fatigue in patients with breast cancer before, during, and after radiation therapy.  Cancer Nurs. 2010;  33 (3) 201-212
• 31 Vernon S D, Whistler T, Cameron B, Hickie I B, Reeves W C, Lloyd A. Preliminary evidence of mitochondrial dysfunction associated with post-infective fatigue after acute infection with Epstein Barr virus.  BMC Infect Dis. 2006;  6 15
• 32 Banning M. Influenza: incidence, symptoms and treatment.  Br J Nurs. 2005;  14 (22) 1192-1197
• 33 Dalakas M C. Toxic and drug-induced myopathies.  J Neurol Neurosurg Psychiatry. 2009;  80 (8) 832-838
• 34 Toyooka K, Fujimura H. Iatrogenic neuropathies.  Curr Opin Neurol. 2009;  22 (5) 475-479
• 35 Members of the Mayo Clinic Department of Neurology, Mayo Clinic and Mayo Foundation .Mayo Clinic Examinations in Neurology. 7th ed. St. Louis, MO: Mosby; 1998
• 36 The Guarantors of Brain. Aids to the Examination of the Peripheral Nervous System. 4th ed. Edinburgh: W.B. Saunders; 2000
• 37 Tawil R, Van Der Maarel S M. Facioscapulohumeral muscular dystrophy.  Muscle Nerve. 2006;  34 (1) 1-15
• 38 Turner C, Hilton-Jones D. The myotonic dystrophies: diagnosis and management.  J Neurol Neurosurg Psychiatry. 2010;  81 (4) 358-367
• 39 van Adel B A, Tarnopolsky M A. Metabolic myopathies: update 2009.  J Clin Neuromuscul Dis. 2009;  10 (3) 97-121
• 40 Bogousslavsky J, Perentes E, Regli F, Deruaz J P. Polymyositis with severe facial involvement.  J Neurol. 1982;  228 (4) 277-281
• 41 Brais B. Oculopharyngeal muscular dystrophy: a polyalanine myopathy.  Curr Neurol Neurosci Rep. 2009;  9 (1) 76-82
• 42 Ptáĉek L J, Tawil R, Griggs R C et al.. Sodium channel mutations in acetazolamide-responsive myotonia congenita, paramyotonia congenita, and hyperkalemic periodic paralysis.  Neurology. 1994;  44 (8) 1500-1503
• 43 Sanders D B, El-Salem K, Massey J M, McConville J, Vincent A. Clinical aspects of MuSK antibody positive seronegative MG.  Neurology. 2003;  60 (12) 1978-1980
• 44 Pasnoor M, Wolfe G I, Nations S et al.. Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience.  Muscle Nerve. 2010;  41 (3) 370-374
• 45 O'Neill J H, Murray N MF, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases.  Brain. 1988;  111 (Pt 3) 577-596
• 46 Katz J S, Wolfe G I, Bryan W W, Tintner R, Barohn R J. Acetylcholine receptor antibodies in the Lambert-Eaton myasthenic syndrome.  Neurology. 1998;  50 (2) 470-475
• 47 O'Suilleabhain P, Low P A, Lennon V A. Autonomic dysfunction in the Lambert-Eaton myasthenic syndrome: serologic and clinical correlates.  Neurology. 1998;  50 (1) 88-93
• 48 Reed U C. Congenital muscular dystrophy. Part I: a review of phenotypical and diagnostic aspects.  Arq Neuropsiquiatr. 2009;  67 (1) 144-168
• 49 Sewry C A, Jimenez-Mallebrera C, Muntoni F. Congenital myopathies.  Curr Opin Neurol. 2008;  21 (5) 569-575
• 50 Ozawa E, Noguchi S, Mizuno Y, Hagiwara Y, Yoshida M. From dystrophinopathy to sarcoglycanopathy: evolution of a concept of muscular dystrophy.  Muscle Nerve. 1998;  21 (4) 421-438
• 51 Norwood F, de Visser M, Eymard B, Lochmüller H, Bushby K. EFNS Guideline Task Force . EFNS guideline on diagnosis and management of limb girdle muscular dystrophies.  Eur J Neurol. 2007;  14 (12) 1305-1312
• 52 Feldman B M, Rider L G, Reed A M, Pachman L M. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood.  Lancet. 2008;  371 (9631) 2201-2212
• 53 Selcen D, Ohno K, Engel A G. Myofibrillar myopathy: clinical, morphological and genetic studies in 63 patients.  Brain. 2004;  127 (Pt 2) 439-451
• 54 Amato A A, Barohn R J. Evaluation and treatment of inflammatory myopathies.  J Neurol Neurosurg Psychiatry. 2009;  80 (10) 1060-1068
• 55 Miller T M, Dias da Silva M R, Miller H A et al.. Correlating phenotype and genotype in the periodic paralyses.  Neurology. 2004;  63 (9) 1647-1655
• 56 Day J W, Ricker K, Jacobsen J F et al.. Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum.  Neurology. 2003;  60 (4) 657-664
• 57 Hoffman E P, Fischbeck K H, Brown R H et al.. Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy.  N Engl J Med. 1988;  318 (21) 1363-1368
• 58 Guglieri M, Magri F, D'Angelo M G et al.. Clinical, molecular, and protein correlations in a large sample of genetically diagnosed Italian limb girdle muscular dystrophy patients.  Hum Mutat. 2008;  29 (2) 258-266
• 59 Pautas E, Chérin P, Piette J C et al.. Features of polymyositis and dermatomyositis in the elderly: a case-control study.  Clin Exp Rheumatol. 2000;  18 (2) 241-244
• 60 Wong E T, Cobb C, Umehara M K et al.. Heterogeneity of serum creatine kinase activity among racial and gender groups of the population.  Am J Clin Pathol. 1983;  79 (5) 582-586
• 61 Wakefield S E, Dimberg E L, Moore S A, Tseng B S. Dystrophinopathy presenting with arrhythmia in an asymptomatic 34-year-old man: a case report.  J Med Case Reports. 2009;  3 8625
• 62 Eymard B, Brouet J C, Collin H, Chevallay M, Bussel A, Fardeau M. Late-onset rod myopathy associated with monoclonal gammopathy.  Neuromuscul Disord. 1993;  3 (5-6) 557-560
• 63 Milone M, Katz A, Amato A A et al.. Sporadic late onset nemaline myopathy responsive to IVIg and immunotherapy.  Muscle Nerve. 2010;  41 (2) 272-276
• 64 Sundblad A, Porwit A, Ostad M et al.. Antibody reactivities to skeletal muscle proteins in a patient with lambda light chain secreting multiple myeloma, generalised amyloidosis and rhabdomyolysis.  Eur J Haematol. 2001;  67 (3) 189-193
• 65 Chapin J E, Kornfeld M, Harris A. Amyloid myopathy: characteristic features of a still underdiagnosed disease.  Muscle Nerve. 2005;  31 (2) 266-272
• 66 Wexler R K, Elton T, Pleister A, Feldman D. Cardiomyopathy: an overview.  Am Fam Physician. 2009;  79 (9) 778-784
• 67 Engel A G, Ohno K, Sine S M. Congenital myasthenic syndromes: progress over the past decade.  Muscle Nerve. 2003;  27 (1) 4-25
• 68 Engel A G, Shen X M, Selcen D, Sine S M. Further observations in congenital myasthenic syndromes.  Ann N Y Acad Sci. 2008;  1132 104-113
• 69 Conti-Fine B M, Milani M, Kaminski H J. Myasthenia gravis: past, present, and future.  J Clin Invest. 2006;  116 (11) 2843-2854
• 70 Grob D. Course and management of myasthenia gravis.  J Am Med Assoc. 1953;  153 (6) 529-532
• 71 Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis.  Muscle Nerve. 2008;  37 (2) 141-149
• 72 D'Amelio M, Di Benedetto N, Ragonese P et al.. Dropped head as an unusual presenting sign of myasthenia gravis.  Neurol Sci. 2007;  28 (2) 104-106
• 73 Nations S P, Wolfe G I, Amato A A, Jackson C E, Bryan W W, Barohn R J. Distal myasthenia gravis.  Neurology. 1999;  52 (3) 632-634
• 74 Renard D, Castelnovo G, Labauge P. Distal myasthenia gravis.  Acta Neurol Belg. 2008;  108 (3) 107-108
• 75 Kim W H, Kim J H, Kim E K et al.. Myasthenia gravis presenting as isolated respiratory failure: a case report.  Korean J Intern Med. 2010;  25 (1) 101-104
• 76 McConville J, Farrugia M E, Beeson D et al.. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis.  Ann Neurol. 2004;  55 (4) 580-584
• 77 Evoli A, Tonali P A, Padua L et al.. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis.  Brain. 2003;  126 (Pt 10) 2304-2311
• 78 Larner A J. The place of the ice pack test in the diagnosis of myasthenia gravis.  Int J Clin Pract. 2004;  58 (9) 887-888
• 79 Benatar M. A systematic review of diagnostic studies in myasthenia gravis.  Neuromuscul Disord. 2006;  16 (7) 459-467
• 80 Meriggioli M N, Sanders D B. Advances in the diagnosis of neuromuscular junction disorders.  Am J Phys Med Rehabil. 2005;  84 (8) 627-638
• 81 Howard Jr F M, Lennon V A, Finley J, Matsumoto J, Elveback L R. Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis.  Ann N Y Acad Sci. 1987;  505 526-538
• 82 Chan K H, Lachance D H, Harper C M, Lennon V A. Frequency of seronegativity in adult-acquired generalized myasthenia gravis.  Muscle Nerve. 2007;  36 (5) 651-658
• 83 Kiessling W R, Finke R, Kotulla P, Schleusener H. Circulating TSH-binding inhibiting immunoglobulins in myasthenia gravis.  Acta Endocrinol (Copenh). 1982;  101 (1) 41-46
• 84 Chagnac Y, Hadani M, Goldhammer Y. Myasthenic crisis after intravenous administration of iodinated contrast agent.  Neurology. 1985;  35 (8) 1219-1220
• 85 Richard V S, Al-Ismail D, Salamat A. Should we test TPMT enzyme levels before starting azathioprine?.  Hematology. 2007;  12 (4) 359-360
• 86 Keesey J C. Clinical evaluation and management of myasthenia gravis.  Muscle Nerve. 2004;  29 (4) 484-505
• 87 Skeie G O, Apostolski S, Evoli A et al.. Guidelines for the treatment of autoimmune neuromuscular transmission disorders.  Eur J Neurol. 2006;  13 (7) 691-699
• 88 Lebrun C, Bourg V, Tieulie N, Thomas P. Successful treatment of refractory generalized myasthenia gravis with rituximab.  Eur J Neurol. 2009;  16 (2) 246-250
• 89 Muscle Study Group . A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis.  Neurology. 2008;  71 (6) 394-399
• 90 Sanders D B, Hart I K, Mantegazza R et al.. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis.  Neurology. 2008;  71 (6) 400-406
• 91 Hehir M K, Burns T M, Alpers J, Conaway M R, Sawa M, Sanders D B. Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients.  Muscle Nerve. 2010;  41 (5) 593-598
• 92 Gronseth G S, Barohn R J. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.  Neurology. 2000;  55 (1) 7-15
• 93 Masaoka A, Yamakawa Y, Niwa H et al.. Extended thymectomy for myasthenia gravis patients: a 20-year review.  Ann Thorac Surg. 1996;  62 (3) 853-859
• 94 Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy .Available at: http://clinicaltrials.gov/ct2/show/study/NCT00294658 Accessed June 4, 2010
• 95 Tim R W, Massey J M, Sanders D B. Lambert-Eaton myasthenic syndrome: electrodiagnostic findings and response to treatment.  Neurology. 2000;  54 (11) 2176-2178
• 96 Lennon V A, Lambert E H. Autoantibodies bind solubilized calcium channel-ω-conotoxin complexes from small cell lung carcinoma: a diagnostic aid for Lambert-Eaton myasthenic syndrome.  Mayo Clin Proc. 1989;  64 (12) 1498-1504
• 97 McEvoy K M, Windebank A J, Daube J R, Low P A. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome.  N Engl J Med. 1989;  321 (23) 1567-1571
• 98 Wirtz P W, Verschuuren J J, van Dijk J G et al.. Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study.  Clin Pharmacol Ther. 2009;  86 (1) 44-48
• 99 Nobile-Orazio E. Multifocal motor neuropathy.  J Neuroimmunol. 2001;  115 (1-2) 4-18
• 100 Slee M, Selvan A, Donaghy M. Multifocal motor neuropathy: the diagnostic spectrum and response to treatment.  Neurology. 2007;  69 (17) 1680-1687
• 101 Taylor B V, Wright R A, Harper C M, Dyck P J. Natural history of 46 patients with multifocal motor neuropathy with conduction block.  Muscle Nerve. 2000;  23 (6) 900-908
• 102 Magistris M, Roth G. Motor neuropathy with multifocal persistent conduction blocks.  Muscle Nerve. 1992;  15 (9) 1056-1057
• 103 Kaji R, Shibasaki H, Kimura J. Multifocal demyelinating motor neuropathy: cranial nerve involvement and immunoglobulin therapy.  Neurology. 1992;  42 (3 Pt 1) 506-509
• 104 Olney R K. American Association of Electrodiagnostic Medicine . Guidelines in electrodiagnostic medicine. Consensus criteria for the diagnosis of partial conduction block.  Muscle Nerve Suppl. 1999;  8 (Suppl 8) S225-S229
• 105 Olney R K, Lewis R A, Putnam T D, Campellone Jr J V. American Association of Electrodiagnostic Medicine . Consensus criteria for the diagnosis of multifocal motor neuropathy.  Muscle Nerve. 2003;  27 (1) 117-121
• 106 Pestronk A, Cornblath D R, Ilyas A A et al.. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside.  Ann Neurol. 1988;  24 (1) 73-78
• 107 Nobile-Orazio E, Cappellari A, Meucci N et al.. Multifocal motor neuropathy: clinical and immunological features and response to IVIg in relation to the presence and degree of motor conduction block.  J Neurol Neurosurg Psychiatry. 2002;  72 (6) 761-766
• 108 Chaudhry V, Corse A M, Cornblath D R et al.. Multifocal motor neuropathy: response to human immune globulin.  Ann Neurol. 1993;  33 (3) 237-242
• 109 Azulay J P, Blin O, Pouget J et al.. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study.  Neurology. 1994;  44 (3 Pt 1) 429-432
• 110 Van den Berg L H, Kerkhoff H, Oey P L et al.. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study.  J Neurol Neurosurg Psychiatry. 1995;  59 (3) 248-252
• 111 Federico P, Zochodne D W, Hahn A F, Brown W F, Feasby T E. Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study.  Neurology. 2000;  55 (9) 1256-1262
• 112 Léger J M, Chassande B, Musset L, Meininger V, Bouche P, Baumann N. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study.  Brain. 2001;  124 (Pt 1) 145-153
• 113 Baumann A, Hess C W, Sturzenegger M. IVIg dose increase in multifocal motor neuropathy: a prospective six month follow-up.  J Neurol. 2009;  256 (4) 608-614
• 114 Krarup C, Stewart J D, Sumner A J, Pestronk A, Lipton S A. A syndrome of asymmetric limb weakness with motor conduction block.  Neurology. 1990;  40 (1) 118-127
• 115 Feldman E L, Bromberg M B, Albers J W, Pestronk A. Immunosuppressive treatment in multifocal motor neuropathy.  Ann Neurol. 1991;  30 (3) 397-401
• 116 Tan E, Lynn D J, Amato A A et al.. Immunosuppressive treatment of motor neuron syndromes. Attempts to distinguish a treatable disorder.  Arch Neurol. 1994;  51 (2) 194-200
• 117 Brannagan III T H, Alaedini A, Gladstone D E. High-dose cyclophosphamide without stem cell rescue for refractory multifocal motor neuropathy.  Muscle Nerve. 2006;  34 (2) 246-250
• 118 Strong M J, Grace G M, Freedman M et al.. Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis.  Amyotroph Lateral Scler. 2009;  10 (3) 131-146
• 119 Brooks B R, Miller R G, Swash M, Munsat T L. World Federation of Neurology Research Group on Motor Neuron Diseases . El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis.  Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;  1 (5) 293-299
• 120 Fisher M, Mateer J E, Ullrich I, Gutrecht J A. Pyramidal tract deficits and polyneuropathy in hyperthyroidism, Combination clinically mimicking amyotrophic lateral sclerosis.  Am J Med. 1985;  78 (6 Pt 1) 1041-1044
• 121 Jackson C E, Amato A A, Bryan W W, Wolfe G I, Sakhaee K, Barohn R J. Primary hyperparathyroidism and ALS: is there a relation?.  Neurology. 1998;  50 (6) 1795-1799
• 122 Weihl C C, Lopate G. Motor neuron disease associated with copper deficiency.  Muscle Nerve. 2006;  34 (6) 789-793
• 123 Di Rocco A, Simpson D M. AIDS-associated vacuolar myelopathy.  AIDS Patient Care STDS. 1998;  12 (6) 457-461
• 124 Hemmer B, Glocker F X, Kaiser R, Lücking C H, Deuschl G. Generalised motor neuron disease as an unusual manifestation of Borrelia burgdorferi infection.  J Neurol Neurosurg Psychiatry. 1997;  63 (2) 257-258
• 125 Baud P, Parant E, Loison F, Ménage J J. [IgM kappa lymphoma with antisulfatide antibodies revealed by cervical motor neuropathy simulating amyotrophic lateral sclerosis].  Rev Med Interne. 1998;  19 (4) 275-278
• 126 Miller R G, Jackson C E, Kasarskis E J Quality Standards Subcommittee of the American Academy of Neurology et al. Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.  Neurology. 2009;  73 (15) 1218-1226
• 127 Miller R G, Jackson C E, Kasarskis E J Quality Standards Subcommittee of the American Academy of Neurology et al. Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.  Neurology. 2009;  73 (15) 1227-1233